title: 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk: what is so controversial?
abstract: In November 2013, the American College of Cardiology and American Heart Association (ACC/AHA) released a clinical practice guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in adults. The guideline recommendations were developed from a rigorous systematic review of randomized, controlled trials (RCTs) and meta-analyses of RCTs that evaluated ASCVD outcomes. Major recommendations address a healthy lifestyle, identification of groups of patients most likely to experience a net benefit form statin therapy, appropriate intensity of statin therapy to reduce ASCVD, safety, decision-making in primary prevention, monitoring therapy, and appropriate use of nonstatin therapy. Areas of controversy are discussed.
authors.affiliation: Departments of Epidemiology & Medicine, University of Iowa, 145 N Riverside Drive S455 CPHB, Iowa City, IA, 52242, USA, jennifer-g-robinson@uiowa.edu.
authors.forename: Jennifer G
authors.initials: JG
authors.lastname: Robinson
mesh_terms: D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008019:Life Style; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014481:United States
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol